Abiomed, Inc. (ABMD) Advances 3.41% Today: What Should You Do About It?

Hopefully you got into Abiomed, Inc. (NASDAQ:ABMD) early, as today the stock is trading 3.41% or 8.72 points up from last closing price of $255.81, reaching $264.53 at last check. The ABMD share price has risen in 2 of the last 5 days and is down -9.17% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -65,404 shares, and in total 324896 shares valued at $85.945 million were seen changing hands compared with 390300 shares valued at $99.843 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in ABMD stock for the next couple of days.

Abiomed, Inc. (ABMD) shares have notched a 3-month decline of about -9.17%, but has still tumbled -21.3% year to date. By comparison, the stock sank -37.37% over the past 12 months, while it slipped -6.1% over the 1 month. The company’s market cap is around $11.34B, with its short interest ratio standing at 3.38%.

In the current trading session for ABMD, the stock witnessed two major price actions, it rose to a high of $265.02 and was down as much as $256.01 at one point. The high recorded is very low when compared to their 52-week high which is $228. The 52-week high is now at -42.55 distance from current price. Their recent low of $459.75 represents a 15.85% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ABMD is $336.88, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Abiomed, Inc. earned $5.61 per share in the trailing 12 months and has a P/E ratio of 47.15. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 105.1 and higher compared to the sector’s average of 34.38. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. ABMD also has P/S multiple of 15.24. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 21.71x.

The company recorded an interesting insider sale transaction by the Director on May 08, 2019. A Securities and Exchanges Commission filings show that Martin P Sutter sold a total of 4,664 ABMD shares that day for a sum of around $1,212,500. The filings show that the insider now retains 192,550 shares, currently worth $50,935,252. Abiomed, Inc. (ABMD) insiders have acquired 104,069 shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to 171,281 shares. In total, individual insiders traded 275,350 shares in the business, which makes up 37.125% of 741,688 shares that were traded over a year. In the past 12 months, insiders have purchased 280,515 shares while the seller parted with 461,173 shares.

ABMD‘s last price was down -16.51% as compared to the average trading price of 50 days recorded at $316.84 while enlarging the period to 200 trading days, the average closing price was $261.91. At present, there are 44.32 million in the total number of common shares owned by the public and among those 44.22 million shares have been available to trade. The percentage of shares being held by the company management was 1.6% while institutions stake was 89.5%. The company has generated positive returns on equity over the last 12 months (31.4%). It managed to keep its gross profit margin at 83.2% over the past 12 months.

When assessing the full upside of the ABMD stock, there is another set of technicals that should be looked into and considered. Its 2.7% gain from moving average of $257.58 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0.31 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Abiomed, Inc. — 3 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $400.3333 on shares of Abiomed, Inc. (NASDAQ:ABMD), which corresponds to 51.10% upside potential than its current market price of $264.53 and implies potential despite the recent advance in the price. However, their current target price has fallen from $420.25 a month ago and is down handily from the consensus target of $450.25 a quarter ago.

In the last five years, the EPS of the company has been roughly 99.7%. Though the percentage looks encouraging, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 28.5%. The revenue of the company has risen at an average annualized rate of about 33.2 over the last five years. The company recently recorded an increase of 18.8%, but this figure is rather attractive.

Let’s briefly check the hedge fund interest towards ABMD stock. Country Trust Bank added position in the company after it grew 1.3% or 106,889 shares of its common stock. The hedge fund now owns 108,279 shares worth $28,643,044, SEC documents show. Chicago Capital LLC shored up assets in the stock as 66625.82 shares have been purchased, increasing its stake by 6.1% to 70,690 shares which are currently valued at $18,699,626. In addition, Harbour Capital Advisors LLC recently reported that it now owns 1,340 shares making a total of $354,470 based on the recent price. This refelects a change of 91.4% in their ownership.